Ocugen Completes Phase 3 Enrollment for RP Gene Therapy, Eyes 2027 Approval
Event summary
- Ocugen completed enrollment for its Phase 3 liMeliGhT trial for OCU400, a gene therapy for retinitis pigmentosa (RP), with 140 patients randomized.
- Topline Phase 3 data expected in 1Q 2027, with potential approval in 2027.
- Positive 3-year Phase 1/2 data shows sustained visual function improvement with no new safety concerns.
- OCU400 is the only broad RP gene-agnostic trial and the largest known Phase 3 orphan gene therapy trial.
The big picture
Ocugen's completion of Phase 3 enrollment for OCU400 marks a critical step in addressing a significant unmet need in RP treatment, a condition affecting hundreds of thousands of patients globally. The gene-agnostic approach of OCU400 differentiates it from existing gene replacement therapies, which are limited to single mutations. Success could position Ocugen as a leader in modifier gene therapies for rare retinal diseases.
What we're watching
- Regulatory Pathway
- Whether the FDA and EMA will accept the U.S.-based trial data for approval decisions.
- Clinical Efficacy
- The durability of visual function improvements observed in the Phase 3 trial.
- Market Potential
- The pace at which Ocugen can commercialize OCU400 if approved, given the broad RP patient population.
Related topics